Neuropilin-1 blockade with optimized nanobody formats as novel cancer therapy

Project Details


Immunotherapy has meant a breakthrough in the treatment of some cancers. However, the majority of patients remain unresponsive and multipce cancer types are refractory to immunotherapy. Hence, novel approaches are needed to bridge the gap in response rates. Neuropilin-1 (NRP1) is often overexpressed within tumors and correlates with a worse prognosis, likely due to its immune suppressive caoacity.
Effective start/end date1/01/2231/12/22


  • Immunotherapy
  • Neuropilin-1
  • Nanobody
  • cancer therapy

Flemish discipline codes 2018-2023

  • Other medical and health sciences not elsewhere classified


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.